INVESTOR PRESENTATION

2022 **INTERIM RESULTS**

Disclaimer

By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations:

The information in this presentation has been prepared by representatives of Venus Medtech(Hangzhou) Inv. (the " Company"） for use in presentation by the company at investor meetings for information purposes. No part of this presentation should form the basis of , or be relied on in connection with, any contract or commitment or investment decision whatsoever.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of its directors, supervisors, officers, partners, employees, affiliates, agents, advisors or representatives shall have any responsibility or liability whatsoever(for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially.

This presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor any of its directors, supervisors, officers, partners, employees, affiliates, agents, advisors or representatives is under an obligation to update, revise or affirm.

The information communicated in this presentation contains certain statements that are or may be forwarding-looking. These statements typically contain words such as "will""may""expert""forecast""plan "and "anticipate "and words of similar import. By their nature forward-looking statement involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, readers should not rely on these forward –looking statements. The Company assumes no responsibility to update the forward-looking statements or to adapt them to future events or developments.

This presentation and the information contained herein does not constitute or form part of any offer to sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company in any jurisdiction. This presentation and the information contained herein is highly confidential and being furnished to you solely for your information and may not be reproduced or redistributed in any manner to any other person, in whole or in part. In particular, neither the information contained in this presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or in the United States, Canada, Australia, Japan, Hong Kong or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other national securities laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will be accepted.

By attending this presentation, you acknowledge that you will be solely responsible for you own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. Any decision to purchase securities in the context of a proposed offering of securities, if any, should be made solely on the basis of information contained in an offering circular or prospectus prepared in relation to such offering.

By reviewing this presentation, you are deemed to have represented and agreed that you and any customers you represent are neither(i) a "qualified institutional buyer"(within the meaning of Rule 14A under the United States Securities Act of 1933, as amended), or(ii) outside the Unites States. Yor re also deemed to have represented and agreed that you and any customers you represent are professional investors as defined in the Securities and Futures Ordinance(Chapter 571 of the Laws of Hong Kong) and any rules made thereunder.

CONTENT

01 BUSINESS HIGHLIGHTS

Business Highlights

2022 H1

Pipeline Expanded, Covering TPVR for the First Time

- ✓ April: VenusP-Valve obtained CE marking under MDR
- ✓ May: VenusA-Pro NMPA approved
- ✓ July: VenusP-Valve NMPA approved

Global Breakthrough, Key System Established

- ✓ Overseas income increased rapidly
- ✓ Overseas clinical, regulatory registration and sales system established

Stable Domestic Market Share

- ✓ Hospital coverage: 375
- ✓ Sales team: 260
- ✓ Implantations in 2022H1: 1800

2022 H2

Global Multi-center Clinical Trial Accelerating

- ➢ VenusP-Valve US IDE clinical trial is expected to start next year
- ➢ Liwen RF European clinical trial is expected to start next year
- ➢ Cardiovalve China, US, Europe clinical trials conduct simultaneously

Overseas Commercialization Deepened Continuously

- ➢ Overseas income continued to increase
- ➢ Overseas market influence enhanced

Domestic Commercialization in Profit

- ➢ Optimize sales efficiency
- ➢ Improve the output of single hospital at medium-level and top hospitals
- ➢ Continuously reduce production costs and expenses

02 GLOBAL MARKET

VenusP-Valve： Globalization Breakthrough Historically



Making Strides in Global Registration, with Breakthroughs in China, Europe, and the U.S.

- **April:** VenusP-Valve obtained CE marking under MDR, becoming the first Class III implantable cardiovascular device approved under the new MDR.
- **June**: The Investigator Meeting for VenusP-Valve U.S. Investigational Device Exemption (IDE) Clinical Study was held, making a good start for U.S. trials. And the Japan-US Harmonization By Doing Program was agreed upon by the FDA and PMDA with a plan to conduct clinical trials in the U.S. and Japan simultaneously, which will accelerate the registration and marketing of VenusP-Valve in both countries.
- **July**: VenusP-Valve approved by China's NMPA, who has accepted the overseas clinical trials data as clinical evaluation data, that is, the CE clinical trial data was applied for the registration application.

Passed the CE MDR Quality Management System Review

- March: MDSAP review started
- March-April: VenusP-Valve CE MDR review finished
- May & July: VenusP-Valve remote and on-site supervision audit finished

Global Commercialization Layout

Expand global network for direct selling and distribution, preferring Germany, France, Switzerland, Austria, Belgium, Luxembourg and the Netherlands for direct selling, with a view to establish brand awareness in mainstream markets and gain more control over channels.



VenusP-Valve: Commercialization Progress

Continue to Enter New Countries

Britain, Ireland, Germany, France, Italy, Denmark, Switzerland, Austria, Belgium, Spain, Portugal, Greece, Poland and other 14 countries

Outstanding Clinical Outcomes

Well-recognized by international Experts

Clinical application for 9 years, VenusP-Valve has been used in nearly 300 cases for humanitarian reasons, spanning more than 20 countries and regions;

Approved by FDA for compassionate use in two cases in the U.S.. And the cases were completed successfully at University of Virginia Advanced Cardiac Valve Center

Professional Sales Team to Expand Sales Network

The overseas sales team covers Europe, Latin America and Southeast Asia

Sales channels include agents and direct sales



Global Quality Management System

VENUSMEDTECH™





Global Intellectual Properties Portfolio

Leading Quantity among Domestic Competitors

As of June 30 2022, 786 patents and patents under application, and 319 authorized invention patents.

Wide Coverage

IP covers China, U.S., Europe, Japan, Canada, Russia, India, Brazil, etc.

80% invention patents



In-depth Layout

Detailed IP portfolio in key technology such as latest dry-tissue, balloon expandable valve, anti-paravalvular leak technology.

Risk Control

Comprehensive risk control of the entire life cycle of products

Domestic Market：Seek Profitability

TAVR Products in 2022 H1

1800
Implantations

60%
Second-generation TAVR Device Implantations

375
Hospital Coverage

260人
Sales Team

The only Commercial TAVR Device Maker in Profit in China

Mean TAVR Volume at US Hospitals



According to the JACC data *, total sites with at least a TAVR in the U.S. were 669, and mean of site's TAVR volume were 109.7 in year 2019

According to the National Center for Cardiovascular Disease data * , only 10 hospitals exceeded 100 TAVR volume in China in 2021

Continue to Explore Output at High-potential Hospitals

References：1. Carroll et al., STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement, Journal of the American College of Cardiology, Vol 76 21.2020 Accessed from https://doi.org/10.1016/j.jacc.2020.09.595
2. 国家心血管中心，2021年中国结构性心脏病介入技术质控报告（上）瓣膜病篇，2022.01 来源：https://mp.weixin.qq.com/s/xNAlIkNO83SF_tgbsPUvZA

Financial Review

Sales Revenue



Unit: million RMB

China Revenue



Unit: million RMB

Overseas Revenue



Unit: million RMB

03 R&D INNOVATION

Heart Valve Product Pipeline



Cardiovalve Overseas Clinical Progress

Tricuspid

- Implantation completed successfully in 18 patients (compassionate route in Canada, Italy and Germany)
- EFS in Europe ongoing
- EFS in US in preparation, approved as a Breakthrough designated therapy



Mitral

- Clinical study completed successfully in 16 patients, the longest follow-up, of the first patient, is approaching 4 years
- AHEAD EU study commenced in 5 European Countries
- AHEAD US EFS study in preparation

Cardiovalve Global Clinical Trials Layout



EU

- **MR**

AHEAD EU (EFS)
12 centers (Germany, Italy, Greece, Lithuania)

- **TR**

TARGET (EFS)
11 centers in Germany

China

- **MR**

FIM
2 centers preparing

- **TR**

FIM
1 centers preparing

US

- **MR**

AHEAD US (EFS)
4 centers

- **TR**

EFS
5 centers preparing

Next-Generation TAVR Devices

Venus-PowerX

- Dry-tissue Valve
- 100% Retrievable
- Active Anti-PVL Technology
- Self-expanding
- Long-term Durability
- Under FIM Clinical Trial

Venus-Vitae

- Active Anti-PVL Technology
- Dry-tissue Valve
- Wire Lock Design
- Balloon-expandable
- Long-term Durability
- Under FIM Clinical Trial

Liwen RF: Global First HCM Solution

Liwen RF ablation system for treatment of hypertrophic cardiomyopathy (HCM)
Pivotal clinical study ongoing

8 ‰
Morbidity Rate *

1 Million +
HCM Adult Patient*

140-200 Thous
Severe HCM Patient*

R&D ✓ → Animal Experiment ✓ → FIM ✓ → **Pivotal Clinical Study** → **Regulatory Registration**

Prof. Junbo Ge, Prof. Yun Zhang lead the clinical study; Professor Liwen Liu, the inventor of Liwen Procedure is the PI of the study

Main centers include: Xijing Hospital, The Second Affiliated Hospital Zhejiang University School of Medicine, etc.

Planned to enroll 128 patients
Main clinical endpoint: treatment success rate at 6 month

European Clinical trial preparing

References[1]. 中华医学会心血管病学分会中国成人肥厚型心肌病诊断与治疗指南编写组,中华心血管病杂志编辑委员会.中国成人肥厚型心肌病诊断与治疗指南[J].中华心血管病杂志,2017,45(12):1015-1032. DOI:10.3760/cma.j.issn.0253-3758.2017.12.005.

RDN Ultrasound Ablation

Venus Medtech formed a joint venture company, Renaly Ltd, with Healium Medical Ltd. to introduce the next-generation ultrasound ablation technology.

Relevant product is under animal experiment at present.



- **Precise Power Delivery**
- **No Tissue Contact**
- **Real Time Monitoring**

Thanks!